Up-regulated inflammatory factors endothelin, NFκB, TNFα and iNOS involved in exaggerated cardiac arrhythmias in l-thyroxine-induced cardiomyopathy are suppressed by darusentan in rats

Life Sciences

Volumn 79, Issue 19, 2006, Pages 1812-1819

  Xia, Hui Jing ^a   Dai, De Zai ^a   Dai, Yin ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Cardiomyopathy; Endothelin receptor antagonist; Inflammation; l thyroxine; Ventricular fibrillation

Indexed keywords

DARUSENTAN; ENDOTHELIN; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR A; ENDOTHELIN RECEPTOR B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LEVOTHYROXINE; MESSENGER RNA; PREPROENDOTHELIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; CORONARY ARTERY LIGATION; CORONARY REPERFUSION; GENE EXPRESSION; HEART ARRHYTHMIA; HEART LEFT VENTRICLE; HEART VENTRICLE FIBRILLATION; MALE; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; UPREGULATION;

ANIMALS; CARDIOMYOPATHIES; DISEASE MODELS, ANIMAL; ENDOTHELINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; OXIDATION-REDUCTION; PHENYLPROPIONATES; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN A; THYROXINE; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION; VENTRICULAR FIBRILLATION;

EID: 33748952130     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2006.06.007     Document Type: Article

References (51)

1. Alberola Aguilar A.M., Revert F., Moya A., Beltran J., Garcla J., San martin E., Sancho S., and Such L. Intravenous BQ-123 and phosphoramidon reduce ventricular ectopic beats and myocardial infarct size in dogs submitted to coronary occlusion and reperfusion. General Pharmacology 35 3 (2000) 143-147
2. Baltogiannis G.G., Tsalikakis D.G., Mitsi A.C., Hatzistergos K.E., Elaiopoulos D., Fotiadis D., Fotiadis D.I., Kyriakides Z.S., and Kolettis T.M. Endothelin receptor-A blockade decreases ventricular arrhythmias after myocardial infarction in rats. Cardiovascular Research 67 4 (2005) 647-654
3. Browatzki M., Schmidt J., Kubler W., and Kranzhofer R. Endothelin-1 induces interleukin-6 release via activation of the transcription factor NF-kappa B in human vascular smooth muscle cells. Basic Research in Cardiology 95 2 (2000) 98-105
4. Cheng C.M., Hong H.J., Liu J.C., Shih N.L., Juan S.H., Loh S.H., Chan P., Chen J.J., and Cheng T.H. Crucial role of extracellular signal-regulated kinase pathway in reactive oxygen species-mediated endothelin-1 gene expression induced by endothelin-1 in rat cardiac fibroblasts. Molecular Pharmacology 63 5 (2003) 1002-1011
5. Collins T., and Cybulsky M. NF-kappaB: pivotal mediator or innocent bystander in atherogenesis?. The Journal of Clinical Investigation 107 3 (2001) 255-264
6. Cotter G., Kaluski E., Stangl K., Pacher R., Richter C., Milo-Cotter O., Perchenet L., Kobrin I., Kaplan S., Rainisio M., Frey A., Neuhart E., Vered Z., Dingemanse J., and Torre-Amione G. The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure. European Journal of Heart Failure 6 5 (2004) 601-609
7. Crockett T.R., Scott G.A., McGowan N.W., Kane K.A., and Wainwright C.L. Anti-arrhythmic and electrophysiological effects of the endothelin receptor antagonists, BQ-123 and PD161721. European Journal of Pharmacology 432 1 (2001) 71-77
8. Dai D.Z. Vulnerable substrate and multiple ion channel disorder in a diseased heart will be new targets for antiarrhythmic therapy. Acta Pharmacologica Sinica 21 4 (2000) 289-295
9. Dai D.Z. Over-phosphorylation of FKBP12.6, phospholamban, relating to exacerbation of cardiac arrhythmias and failure. Acta Pharmacologica Sinica 25 (2004) 1527 (PL06, abstract)
10. Dai D.Z. Two patterns of ion channelopathy in myocardium: perspectives for development of anti-arrhythmic agents. Current Opinion Investigational Drugs 6 3 (2005) 289-297
11. Dai D.Z., and Yu F. Ion channelopathy and hyperphosphorylation contributing to cardiac arrhythmias. Acta Pharmacologica Sinica 26 8 (2005) 918-925
12. Dai D.Z., Hu H.J., Yang D.M., Hao X.M., Zhang G.Q., Zhou P.A., and Wu C.H. Chronic levothyroxin treatment is associated with ion channel abnormalities in cardiac and neuronal cells. Clinical and Experimental Pharmacology and Physiology 26 10 (1999) 819-821
13. Dai D.Z., Huang M., Ji M., and Liu L.G. Endothelin receptor antagonist activity and selective blocking the ETA and ETB receptors of compound 0213. Journal of China Pharmaceutical University 35 6 (2004) 552-557
14. Dai D.Z., Zhang G.Q., Yang P., and Ma Y.P. Two patterns of ion channelopathies relating to arrhythmias and direct and indirect blockade of ion channels by antiarrhythmic agents. Drug Development Research 58 1 (2003) 42-50
15. Dhalla N.S., Temsah R.M., and Netticadan T. Role of oxidative stress in cardiovascular diseases. Journal of Hypertension 18 6 (2000) 655-673
16. Dhein S., Polontchouk L., Salameh A., and Haefliger J.A. Pharmacological modulation and differential regulation of the cardiac gap junction proteins connexin 43 and connexin 40. Biologie Cellulaire 94 7-8 (2002) 409-422
17. Drew B., and Leeuwenburgh C. Aging and the role of reactive nitrogen species. Annals of the New York Academy of Sciences 959 (2002) 66-81
18. Hao J.M., Dai D.Z., and Yu F. The oxidative stress enhancing effects by l-thyroxin and the antioxidant effects of CPU86017, a derivative of tetrahydroberberine. Progress in Pharmaceutical Sciences 299 9 (2005) 417-421
19. Hirotani S., Otsu K., Nishida K., Higuchi Y., Morita T., Nakayama H., Yamaguchi O., Mano T., Matsumura Y., Ueno H., Tada M., and Hori M. Involvement of nuclear factor-κB and apoptosis signal-regulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy. Circulation 105 4 (2002) 509-515
20. Hodt A., Steine K., and Atar D. Medical and ventilatory treatment of acute heart failure. Tidsskrift for den Norske Laegeforening 126 6 (2006) 749-752
21. Hu H.J., and Dai D.Z. l-thyroxin affects involvement of H1, 5HT2, prostaglandin receptors and the endothelin NO system in allergic vascular response in guinea pigs. Drug Development Research 58 1 (2003) 125-130
22. Huang M., Ji M., and Dai D.Z. The endothelin receptor antagonist 0213 reduces l-thyroxin cardiac hypertrophy and inhibits calcium mobilization in vascular smooth contraction. Drug Development Research 55 (2002) 12 (abstract)
23. Kadenbach B. Intrinsic and extrinsic uncoupling of oxidative phosphorylation. Biochimica et Biophysica Acta 1604 2 (2003) 77-94
24. Klipper E., Gilboa T., Levy N., Kisliouk T., Spanel-Borowski K., and Meidan R. Characterization of endothelin-1 and nitric oxide generating systems in corpus luteum-derived endothelial cells. Reproduction 128 4 (2004) 463-473
25. Libby P., Ridker P.M., and Maseri A. Inflammation and atherosclerosis. Circulation 105 9 (2002) 1135-1143
26. Liu F., and Gutstein D.E. The cardiac gap junction: a potential therapeutic target in the treatment of heart disease. The Mount Sinai Journal of Medicine 69 6 (2002) 421-424
27. Liu Q., Ji M., and Dai D.Z. Matrix metalloproteinse changes in rat hypertrophic myocardium induced by levo-thyroxine and the effect of a new endothelin receptor antagonist CPU0213. Journal of China Pharmaceutical University 35 2 (2004) 150-155
28. Lloyd-Jones D.M., Larson M.G., Leip E.P., Beiser A., D'Agostino R.B., Kannel W.B., Murabito J.M., Vasan R.S., Benjamin E.J., and Levy D. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 106 24 (2002) 3068-3072
29. Maekawa N., Wada H., Kanda T., Niwa T., Yamada Y., Saito K., Fujiwara H., Sekikawa K., and Seishima M. Improved myocardial ischaemia/reperfusion injury in mice lacking tumor necrosis factor-alpha. Journal of the American College of Cardiology 39 7 (2002) 1229-1235
30. Merkely B., Szabo T., Geller L., Kiss O., Horkay F., Raschack M., and Juhasa-Nagy A. The selective endothelin-A-receptor antagonist LU135252 inhibits the direct arrhythmogenic action of endothelin-1. Journal of Cardiovascular Pharmacology 36 5 Suppl 1 (2000) 314-316
31. Polontchouk L., Ebelt B., Jackels M., and Dhein S. Chronic effects of endothelin 1 and angiotensin II on gap junctions and intercellular communication in cardiac cells. The FASEB Journal 16 1 (2002) 87-89
32. Rossen R.D., and Mann D.L. Myocardial inflammation. In: Rich R.R. (Ed). Clinical Immunology: Principles and Practice. 2nd ed. (2001), Mosby, New York 80.1-80.15
33. Salameh A., and Dhein S. Pharmacology of gap junctions. New pharmacological targets for treatment of arrhythmia, seizure and cancer?. Biochimica et Biophysica Acta 1719 1-2 (2005) 36-58
34. Sanders P., Hsu L.F., Hocini M., Jais P., Takahashi Y., Rotter M., Sacher F., Pasquie J.L., Arentz T., Scavee C., Garrigue S., Clementy J., and Haissaguerre M. Mapping and ablation of ventricular fibrillation. Minerva Cardioangiologica 52 3 (2004) 171-181
35. Sawyer D.B., Siwik D.A., Xiao L., Pimentel D.R., Singh K., and Colucci W.S. Role of oxidative stress in myocardial hypertrophy and failure. Journal of Molecular and Cellular Cardiology 34 4 (2002) 379-388
36. Shohet R.V., Kisanuki Y.Y., Zhao X.S., Siddiquee Z., Franco F., and Yanagisawa M. Mice with cardiomyocyte-specific disruption of the endothelin-1 gene are resistant to hyperthyroid cardiac hypertrophy. Proceedings of the National Academy of Sciences of the United States of America 101 (2004) 2088-2093
37. Tribulova N., Shneyvays V., Mamedova L.K., Moshel S., Zinmar T., Shainberg A., Manoach M., Weismann P., and Kostin S. Enhanced connexin-43 and alpha-sarcomeric actin expression in cultured heart myocytes exposed to triiodo-l-thyronine. Journal of Molecular Histology 35 5 (2004) 463-470
38. Vago H., Soos P., Zima E., Geller L., Kekesi V., Andrasi T., Szabo T., Juhasa-Nagy A., and Merkely B. The ET(A) receptor antagonist LU 135252 has no electrophysiological or anti-arrhythmic effects during myocardial ischaemia/reperfusion in dogs. Clinical Science 103 Suppl 48 (2002) 223S-227S
39. Wang H.L., Li S.B., and Dai D.Z. Change on L-type calcium current in single guinea pig hypertrophic ventricular myocytes induced by levo-thyroxin. Journal of China Pharmaceutical University 31 2 (2000) 130-134
40. Wang H.L., Dai D.Z., Gao F., Zhang Y.P., and LU F. Dispersion of ventricular mRNA of RyR2 and SERCA2a associated with arrhythmogenesis in rats. Acta Pharmacologica Sinica 25 6 (2004) 738-743
41. Wang Y.Q., Shi Y.P., and Dai D.Z. Therapeutic effects of CPU86017 on acute and chronic congestive cardiac failure mediated by reducing ET-1, NOS and oxidative stress in rats. Drug Development Research 63 (2004) 22-32
42. Wehrens X.H., Lehnart S.E., Huang F., Vest J.A., Reiken S.R., Mohler P.J., Sun J., Guatimosim S., Song L.S., Rosemblit N., D'Armiento J.M., Napolitano C., Memmi M., Priori S.G., Lederer W.J., and Marks A.R. FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell 113 7 (2003) 829-840
43. Woods M., Wood E.G., Bardswell S.C., Bishop-Bailey D., Barker S., Wort S.J., Mitchell J.A., and Warner T.D. Role for nuclear factor-κB and signal transducer and activator of transcription 1/interferon regulatory factor-1 in cytokine-induced endothelin-1 release in human vascular smooth muscle cells. Molecular Pharmacology 64 4 (2003) 923-931
44. Wu X.D., Dai D.Z., Zhang Q.P., and Gao F. Propranolol and verapamil inhibit mRNA expression of RyR2 and SERCA in l-thyroxin-induced rat ventricular hypertrophy. Acta Pharmacologica Sinica 25 3 (2004) 347-351
45. Xu H., Lin L., and Yuan W.J. Antiarrhythmic effect of endothelin-A receptor antagonist on acute ischemic arrhythmia in isolated rat heart. Acta Pharmacologica Sinica 24 1 (2003) 37-44
46. Yang L.L., Gros R., Kabir M.G., Sadi A., Gotlieb A.I., Husain M., and Stewart D.J. Conditional cardiac overexpression of endothelin-1 induces inflammation and dilated cardiomyopathy in mice. Circulation 109 2 (2004) 255-261
47. Yang P., and Dai D.Z. l-thyroxin induced vasodilatation impairment and increased vascular response to norepinephrine are mediated by dysfunctional NO release. Drug Development Research 58 1 (2003) 116-124
48. Yu F., Dai D.Z., An L.F., and Guo X.F. Heart hypertrophy induced by levothyroxine aggravates ischemic lesion and reperfusion arrhythmias in rats. Acta Pharmacologica Sinica 18 1 (1997) 71-74
49. + current in guinea pig hypertrophied ventricular myocytes induced by thyroxin. Chinese Pharmacological Bulletin 17 2 (2001) 1-4
50. + current in cardiomyocytes from hypertrophied guinea pig hearts induced by thyroxin. Journal of China Pharmaceutical University 31 6 (2000) 451-454
51. Zhang T.T., Cui B., Dai D.Z., and Tang X.Y. Pharmacological effect of CPU86017 on hypoxic pulmonary hypertension in rats: mediated by direct inhibition of calcium channels and antioxidant action, but indirect effects on the ET-1 pathway. Journal Cardiovascular Pharmacology 46 6 (2005) 727-734